ABU DHABI, UAE, May 28, 2025 — Halia Therapeutics, a biopharmaceutical company in the clinical stage focused on treatments that target the body’s innate immune system, has announced that its CEO, Dr. David Bearss, will be the keynote speaker at the Med Investment Forum 2025. The forum is scheduled for May 29, 2025, at the Rotana Beach Hotel in Abu Dhabi, UAE.
Dr. Bearss’s presentation is entitled: “Pioneering a New Era of Medicine by Unlocking the Body’s Power of Genetic Resilience.”
The keynote address will delve into how understanding individuals who remain healthy despite genetic predispositions to disease is revolutionizing therapeutic development. Halia’s research utilizes extensive genomic data to create innovative treatments for inflammatory and neurodegenerative conditions.
“The key to overcoming the greatest medical challenges lies in discovering why some people are protected from disease,” Dr. Bearss stated. “At Halia, we are applying this knowledge to develop therapies that modulate the body’s immune response at the molecular level, leading to a new age of precision immunology.”
Advancing Precision Immunology Through Genetic Resilience
Halia Therapeutics is transforming the understanding of how inflammation contributes to serious illnesses through advanced science and a strong development pipeline. The company’s primary programs include HT-6184, a NEK7 allosteric modulator currently in clinical trials for myelodysplastic syndromes (MDS) and obesity, and HT-4253, which is being developed to mimic the protective genetic effect of RAB10 loss-of-function in APOE4 homozygotes who are resistant to Alzheimer’s disease.
The Med Investment Forum, supported by the UAE Ministry of Health and Prevention in collaboration with the World Health Organization (WHO), is a leading global platform that brings together health ministers, investors, biotech executives, and healthtech innovators. Halia’s participation as a keynote speaker highlights the innovation and global impact that the Forum promotes.
This event provides a chance to explore groundbreaking biotech solutions and network with investors and decision-makers who are shaping the future of healthcare.
Event Details
- Date: May 29, 2025
- Location: Rotana Beach Hotel, Abu Dhabi, UAE
- Website:
About Halia Therapeutics
Halia Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies that modulate the innate immune system for the treatment of diseases driven by inflammation. By identifying the biological mechanisms behind genetic resilience, Halia is creating innovative treatments for neurodegenerative, hematological, and metabolic disorders. More information is available at
Media Contact
Taylor Avei
Director of Business Development
Halia Therapeutics
SOURCE Halia Therapeutics
“`